Korea Investment CORP Has $60.46 Million Stock Holdings in HCA Healthcare, Inc. $HCA

Korea Investment CORP reduced its position in shares of HCA Healthcare, Inc. (NYSE:HCA) by 5.4% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 141,863 shares of the company’s stock after selling 8,126 shares during the quarter. Korea Investment CORP’s holdings in HCA Healthcare were worth $60,462,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Munich Reinsurance Co Stock Corp in Munich acquired a new position in shares of HCA Healthcare during the 3rd quarter worth about $2,374,000. Angeles Wealth Management LLC lifted its holdings in shares of HCA Healthcare by 2.4% during the third quarter. Angeles Wealth Management LLC now owns 1,014 shares of the company’s stock worth $432,000 after buying an additional 24 shares during the last quarter. Evexia Wealth LLC grew its stake in shares of HCA Healthcare by 16.7% in the third quarter. Evexia Wealth LLC now owns 18,046 shares of the company’s stock worth $7,411,000 after acquiring an additional 2,589 shares during the last quarter. First Trust Advisors LP raised its stake in HCA Healthcare by 46.5% during the 3rd quarter. First Trust Advisors LP now owns 127,552 shares of the company’s stock valued at $54,363,000 after purchasing an additional 40,476 shares during the last quarter. Finally, HUB Investment Partners LLC grew its position in HCA Healthcare by 42.1% in the 3rd quarter. HUB Investment Partners LLC now owns 1,685 shares of the company’s stock worth $718,000 after purchasing an additional 499 shares during the last quarter. 62.73% of the stock is owned by institutional investors and hedge funds.

HCA Healthcare Trading Down 0.2%

NYSE HCA opened at $533.63 on Monday. The firm has a market cap of $119.33 billion, a price-to-earnings ratio of 18.80, a PEG ratio of 1.64 and a beta of 1.34. HCA Healthcare, Inc. has a 1-year low of $310.18 and a 1-year high of $552.90. The company has a 50 day moving average of $500.34 and a 200-day moving average of $465.79.

HCA Healthcare (NYSE:HCA) last released its quarterly earnings results on Tuesday, January 27th. The company reported $8.01 EPS for the quarter, topping analysts’ consensus estimates of $7.37 by $0.64. HCA Healthcare had a negative return on equity of 409.11% and a net margin of 8.97%.The business had revenue of $19.51 billion for the quarter, compared to analyst estimates of $19.67 billion. During the same period in the prior year, the company earned $6.22 EPS. HCA Healthcare’s revenue for the quarter was up 6.7% on a year-over-year basis. HCA Healthcare has set its FY 2026 guidance at 29.100-31.500 EPS. On average, analysts forecast that HCA Healthcare, Inc. will post 24.98 earnings per share for the current year.

HCA Healthcare Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 31st. Investors of record on Tuesday, March 17th will be given a dividend of $0.78 per share. This is a positive change from HCA Healthcare’s previous quarterly dividend of $0.72. The ex-dividend date is Tuesday, March 17th. This represents a $3.12 annualized dividend and a yield of 0.6%. HCA Healthcare’s dividend payout ratio is currently 10.15%.

Insider Activity at HCA Healthcare

In other HCA Healthcare news, SVP Jennifer Berres sold 8,020 shares of the business’s stock in a transaction dated Wednesday, February 11th. The shares were sold at an average price of $514.58, for a total value of $4,126,931.60. Following the completion of the transaction, the senior vice president directly owned 11,993 shares of the company’s stock, valued at approximately $6,171,357.94. The trade was a 40.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Michael S. Cuffe sold 1,500 shares of the firm’s stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $498.09, for a total transaction of $747,135.00. Following the completion of the sale, the executive vice president directly owned 30,003 shares of the company’s stock, valued at approximately $14,944,194.27. This represents a 4.76% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 15,214 shares of company stock valued at $7,797,595. Insiders own 1.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on HCA shares. Zacks Research cut shares of HCA Healthcare from a “strong-buy” rating to a “hold” rating in a research note on Thursday, November 27th. Barclays upped their price target on HCA Healthcare from $494.00 to $551.00 and gave the company an “overweight” rating in a report on Wednesday, January 28th. Jefferies Financial Group boosted their price objective on HCA Healthcare from $535.00 to $590.00 and gave the company a “buy” rating in a research report on Wednesday, January 28th. Leerink Partners lifted their price target on shares of HCA Healthcare from $507.00 to $573.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 28th. Finally, Truist Financial increased their price objective on shares of HCA Healthcare from $520.00 to $546.00 and gave the company a “buy” rating in a research note on Wednesday, January 28th. Sixteen investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $534.50.

HCA Healthcare News Summary

Here are the key news stories impacting HCA Healthcare this week:

• Positive Sentiment: Analyst sentiment and research upgrades: several outlets and analysts continue to rate HCA favorably — one consensus snapshot called the stock a “Moderate Buy,” reflecting continued analyst confidence that HCA can grow earnings and return capital to shareholders. Article Title
• Positive Sentiment: Long-term demographic bull case: MarketBeat argues HCA is a likely beneficiary of U.S. aging demographics, noting management’s strong guidance (FY2026 EPS and EBITDA ranges), expanded capex, a $10B repurchase authorization and a raised dividend — all supportive of long‑term growth and shareholder returns. Article Title
• Neutral Sentiment: Analyst estimate tweaks from Zacks: Zacks Research nudged near‑term EPS estimates slightly higher for Q2, Q3 and Q4 2026 and raised FY2026 to $29.63, which supports the earnings outlook, but it kept a “Hold” rating — a modest positive but not a strong endorsement. Article Title
• Neutral Sentiment: Zacks’ view is mixed farther out: while FY2026 estimates were lifted, Zacks trimmed its FY2028 EPS forecast modestly — a sign analysts see near‑term strength but some uncertainty on longer‑term margin expansion. Article Title
• Neutral Sentiment: Local/industry headlines are mixed and mostly non‑company specific: a local hospital (Manchester’s Catholic Medical Center) plans to end outpatient mental‑health services and a leadership hire at Methodist Healthcare were reported — signals about regional capacity and staffing but with limited direct impact on HCA’s large national footprint. Article Title Article Title
• Negative Sentiment: Near‑term policy and revenue risks remain prominent: recent company commentary and market writeups note revenue growth was slightly below expectations in the prior quarter and management flagged $600–$900M of potential EBITDA headwinds from insurance‑exchange changes plus state supplemental payment declines — factors that could cap near‑term upside despite strong EPS. Article Title

HCA Healthcare Profile

HCA Healthcare is a for‑profit operator of healthcare facilities headquartered in Nashville, Tennessee. Founded in 1968, the company owns and operates a network of hospitals and related healthcare facilities and has grown through organic expansion and acquisitions to become a large provider of inpatient and outpatient services.

The company’s core activities include the operation of acute care hospitals, freestanding surgical and emergency centers, and outpatient clinics. HCA’s services encompass inpatient care, surgical services, emergency medicine, diagnostic imaging and laboratory testing, and various outpatient and ambulatory care offerings.